Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in Sweden. It offers inventive systems for in vitro diagnostics systems for infectious diseases. The company's lead product candidate is ASTar, an antibiotic susceptibility testing system used for positive blood cultures. It develops and delivers solutions for healthcare providers. Q-linea AB...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers.
Target Price
The average target price of QLINEA.ST is 53 and suggests 95% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell